Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival

Alexandrakis, Michael G.; Passam, Freda; Sfiridaki, Katerina; Moschandrea, J.; Pappa, Constantina A.; Liapi, Dimitra; Petreli, Elisa; Roussou, Parascevi; Kyriakou, Despina

doi:10.1016/s0145-2126(03)00261-3

Cited by 40 publications

(27 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…As previously reported in MM patients, 18,19 among the 18 cytokines explored (Fig. 3C), a strong, significant increase of VEGF-A and IL18, two angiogenesis-promoting cytokines, 19,20 was evident in Vk*MYC mice at the phase of MM (Figs. 3D and E, respectively).…”

Section: Resultssupporting

confidence: 84%

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma

et al. 2015

View full text Add to dashboard Cite

show abstract

Section: Resultssupporting

confidence: 84%

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma

et al. 2015

View full text Add to dashboard Cite

show abstract

“…IL-18 and CA125 have comparable diagnostic potential. However, since IL-18 has also been observed in patients with squamous cell carcinoma, 39 myeloma, 40 endometriosis and endometrial cancer 41 and T-cell leukemia, 42 it is clear that IL-18 alone cannot be used as a specific marker of ovarian cancer. Although CA125 remains the best individual marker, the combination of CA125, IL-18 and FGF-2 is superior in specificity than using CA125 alone in ovarian cancer diagnosis.…”

Section: Discussionmentioning

confidence: 99%

From gene profiling to diagnostic markers: IL‐18 and FGF‐2 complement CA125 as serum‐based markers in epithelial ovarian cancer

Page

Ouellet

Madore

et al. 2005

Intl Journal of Cancer

View full text Add to dashboard Cite

We used an oligonucleotide-based DNA microarray to identify potential markers in 39 primary cultures of ovarian cancer specimens compared with 11 primary cultures of normal ovarian epithelia. Differential gene expression of IL-18 and FGF-2 was validated on a subset of samples by quantitative PCR and by IHC, using an independent tissue array of 90 cores of 20 normal ovarian surface epithelia and 70 EOCs representing different grades and pathologies of ovarian disease. We further compared, by ELISA, these two markers with CA125 in sera from 25 cancer-free and 47 ovarian cancer patients. IL-18 and FGF-2 proteins were significantly elevated in tumor tissues (p<0.04) and sera (p<0.05) from patients with ovarian cancer. In combination, the three markers (IL-18, FGF-2, and CA125) showed similar sensitivity in scoring for ovarian cancer (35/45 patients) compared to that of CA125 alone (37/45) and significantly improved the specificity of detection (20/25 patients) compared to each marker individually (15/25 for CA125; 18/25 FGF-2; 16/25 for IL-18). In conclusion we show that a combination of the three serum markers (IL-18, FGF-2 and CA125) is associated with EOC, with higher specificity than CA125 alone. Prospective studies with a large cohort of susceptible ovarian cancer patients will be required to expand these findings. ' 2005 Wiley-Liss, Inc.

show abstract

“…Moreover, IL-18 could significantly increase MMP-9 but not MMP-2 production, slightly up-regulate TIMP-1, and clearly induce TIMP-2 secretion, suggesting that IL-18 may in part play a role in the clinical aggressiveness of human myeloid leukemia by stimulating MMP-9 production. Alexandrakis et al [52] determined serum levels of IL-18 in 65 newly diagnosed myeloma patients. IL-18 was significantly higher at stage III in comparison to stages II and I. Cytokine level significantly decreased after treatment.…”

Section: Il-18 In Patients With Cancermentioning

confidence: 99%

Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression

Vidal‐Vanaclocha

Mendoza

Tellería

et al. 2006

Cancer Metastasis Rev

111

107

View full text Add to dashboard Cite

Interleukin-18 (IL-18, interferon [IFN]-gamma-inducing factor) is a proinflammatory cytokine converted to a biologically active molecule by interleukin (IL)-1beta converting enzyme (caspase-1). A wide range of normal and cancer cell types can produce and respond to IL-18 through a specific receptor (IL-18R) belonging to the toll-like receptor family. The activity of IL-18 is regulated by IL-18-binding protein (IL-18bp), a secreted protein possessing the ability to neutralize IL-18 and whose blood level is affected by renal function and is induced by IFNgamma. IL-18 plays a central role in inflammation and immune response, contributing to the pathogenesis and pathophysiology of infectious and inflammatory diseases. Because immune-stimulating effects of IL-18 have antineoplastic properties, IL-18 has been proposed as a novel adjuvant therapy against cancer. However, IL-18 increases in the blood of the majority of cancer patients and has been associated with disease progression and, in some cancer types, with metastatic recurrence risk and poor clinical outcome and survival. Under experimental conditions, cancer cells can also escape immune recognition, increase their adherence to the microvascular wall and even induce production of angiogenic and tumor growth-stimulating factors via IL-18-dependent mechanism. This is particularly visible in melanoma cells. Thus, the role of IL-18 in cancer progression and metastasis remains controversial. This review examines the clinical correlations and biological effects of IL-18 during cancer development and highlights recent experimental insights into prometastatic and proangiogenic effects of IL-18 and the use of IL-18bp against cancer progression.

show abstract

Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival

Cited by 40 publications

References 30 publications

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma

From gene profiling to diagnostic markers: IL‐18 and FGF‐2 complement CA125 as serum‐based markers in epithelial ovarian cancer

Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression

Contact Info

Product

Resources

About